BioSpace News Archive

GRAIL, LLC announced today a partnership with Alignment Health Plan, a national Medicare Advantage health plan from Alignment Healthcare (NASDAQ: ALHC), to provide its Medicare Advantage members access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test.

Ocular Therapeutix, Inc. today announced positive topline results from its Phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease.

Greenwich LifeSciences, Inc. today provides manufacturing and clinical updates on Phase III clinical trial FLAMINGO-01.

GH Research PLC today reported financial results for the third quarter ended September 30, 2021 and gave updates on its business.

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full patent application covering multiple families of psilocin analogs.

Kaleido Biosciences, Inc. today announced the extension and expansion of its research collaboration with Janssen Biotech, Inc. (“Janssen”).

Biohaven Pharmaceutical Holding Company Ltd. today announced that the Board of Directors unanimously elected Vlad Coric, MD to the role of Chairman of the Board of Directors following the retirement of Declan Doogan, MD, effective immediately.

Antios Therapeutics, Inc. today announced two oral presentations will be presented at the Hep DART 2021 meeting being held December 5-9, 2021, in Cabo San Lucas, Mexico.

Biohaven today announced positive topline results from the second pivotal clinical trial (NCT04571060) evaluating the safety and efficacy of its investigational therapy, intranasal zavegepant, for the acute treatment of migraine in adults.

Enveric Biosciences today announced the appointment of Bob Dagher , MD, as Chief Medical Officer.